How to Fight Insurance Denials for Autoimmune Cytopenia Treatment (ITP & AIHA)

Autoimmune cytopenias—primarily immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA)—are rare blood disorders where your immune system mistakenly destroys your own platelets or red blood cells. Treatment often begins with corticosteroids, but many patients require second-line therapies like thrombopoietin receptor agonists (TPO-RAs), rituximab, IVIG, newer oral agents such as Tavalisse or Wayrilz, or even splenectomy. Despite FDA approval and professional society endorsement, insurance companies routinely deny these treatments, citing "not medically necessary," "experimental," or rigid step-therapy requirements that force you to fail multiple cheaper drugs first—even when your hematologist believes delay poses serious risk. This guide explains the most common denial templates, the specific clinical evidence insurers respect, and concrete steps to overturn each type of denial.

Why Insurers Deny Autoimmune Cytopenia Treatments

1. "Not enough prior therapies"

The most frequent denial for TPO-RAs (Promacta, Nplate, Doptelet), Tavalisse, or Wayrilz cites failure to try—and document failure of—corticosteroids, IVIG, rituximab, or sometimes even splenectomy. Insurers demand a strict sequence even when your hematologist judges certain steps unsafe (e.g., surgery in an elderly patient) or futile (e.g., re-trying rituximab after documented non-response).

2. "Off-label / experimental"

Rituximab is FDA-approved for lymphoma and rheumatoid arthritis but not ITP or AIHA; insurers label it "experimental" despite ASH 2019 and ICR 2019 guidelines endorsing it as standard second-line therapy. Similarly, daratumumab for refractory cold AIHA or Evans syndrome carries no FDA indication for cytopenia, triggering automatic denials even when published case series demonstrate efficacy.

3. "Platelet count or hemoglobin too high"

Denials often cite a threshold—"platelets must be <30,000" or "hemoglobin <8 g/dL"—ignoring clinical context. A patient with platelets of 35,000 who bruises heavily, bleeds with menstruation, or requires anticoagulation for atrial fibrillation faces real bleeding risk, yet the insurer's algorithm sees only a number above the cutoff.

4. "Insufficient bleeding (ITP) or transfusion dependence (AIHA) documentation"

Insurers want proof of "clinically significant" disease. For ITP, that means WHO bleeding grade ≥2 (wet purpura, mucosal bleeding, heavy menstruation) or documented emergency-room visits. For AIHA, it means transfusion frequency, symptomatic anemia (dyspnea, fatigue scores), or in cold-agglutinin disease, evidence of acrocyanosis or thrombotic events. Vague notes like "patient reports fatigue" won't suffice.

5. "Duplicate therapy / overlapping mechanism"

Denials for a second TPO-RA (switching Promacta to Nplate, or adding Doptelet) claim "already on similar drug." Likewise, adding Tavalisse (SYK inhibitor) or Wayrilz (BTK inhibitor) while on a TPO-RA triggers "combination not proven" denials, even though the mechanisms differ and combination is recognized in refractory ITP management.

The Citations Insurers Respect

When you appeal, reference these specific guidelines and trials by name and year. Insurance medical directors recognize them; generic phrases like "standard of care" carry less weight.

American Society of Hematology (ASH) 2019 Guidelines for ITP

The 2019 ASH evidence-based guideline conditionally recommends TPO-RAs (eltrombopag, romiplostim) and rituximab as second-line options for adults with ITP lasting ≥3 months who have failed or are intolerant of corticosteroids. ASH explicitly states rituximab may be used off-label and that splenectomy is not mandatory before TPO-RAs.

International Consensus Report (ICR) 2019 for ITP

The Provan et al. ICR, published in Blood (2019), supports TPO-RAs and rituximab after first-line failure and endorses fostamatinib (Tavalisse) for patients who have received at least one prior therapy.

LUNA-3 Trial (Wayrilz Approval, 2025)

Rilzabrutinib (Wayrilz) gained FDA approval on August 29, 2025, for persistent or chronic ITP after ≥1 prior therapy, based on the LUNA-3 phase 3 trial demonstrating platelet response without mandatory prior TPO-RA or rituximab failure.

Hill et al., British Journal of Haematology 2024: Autoimmune Hemolytic Anemia

This consensus review endorses rituximab 375 mg/m² weekly × 4 as second-line therapy for warm AIHA and cold-agglutinin disease, and notes emerging data for daratumumab in refractory cases.

CARDINAL and CADENZA Trials (Enjaymo for Cold-Agglutinin Disease)

Sutimlimab (Enjaymo) was FDA-approved in February 2022 for cold-agglutinin disease based on these two trials, which showed reduced transfusion need and improved hemoglobin in patients with cold-agglutinin titer ≥64 and DAT C3-positive disease.

FDA Approval Dates and Labels

• Promacta (eltrombopag): FDA August 2008, chronic ITP; expanded to pediatric and first-line severe aplastic anemia.
• Nplate (romiplostim): FDA August 2008, chronic ITP; pediatric approval 2018.
• Doptelet (avatrombopag): FDA November 2019, chronic ITP (also approved for thrombocytopenia in chronic liver disease pre-procedure).
• Tavalisse (fostamatinib): FDA April 2018, chronic ITP after ≥1 prior therapy.
• Wayrilz (rilzabrutinib): FDA August 29, 2025, persistent/chronic ITP after ≥1 prior therapy.
• Enjaymo (sutimlimab): FDA February 2022, cold-agglutinin disease.

Cite the FDA approval dates and indications verbatim; insurers cannot credibly call an FDA-approved drug "experimental" for its labeled indication.

How to Argue Against Each Denial Reason

Denial: "Not enough prior therapies—must fail steroids, IVIG, rituximab, and splenectomy first"

Concrete steps:

1. Document what you have tried and the outcomes.

Attach pharmacy records, infusion logs, and CBC trends with dates. For example:

- "Prednisone 1 mg/kg/day × 4 weeks (Nov 2025): platelet rose 8,000 → 62,000, then relapsed to 12,000 on taper."

- "IVIG 1 g/kg × 2 days (Jan 2026, March 2026): transient response to 110,000 by day 5, back to 18,000 by day 21."

- "Rituximab 375 mg/m² weekly × 4 (Feb–March 2026): no platelet response at 8 weeks post-treatment."

2. Explain why skipped therapies are contraindicated or futile.

- If the insurer demands splenectomy: "Patient is 74 years old with COPD (FEV1 58% predicted) and atrial fibrillation requiring uninterrupted anticoagulation (apixaban 5 mg BID, CHA₂DS₂-VASc score 4). Surgical risk is prohibitive. ASH 2019 explicitly states splenectomy is not mandatory before TPO-RA."

- If rituximab already failed: "Patient received full course rituximab (375 mg/m² × 4) with documented non-response (platelets 9,000 pre-treatment, 11,000 at 8 weeks post). Re-treatment is not indicated per ICR 2019."

3. Cite ASH 2019 / ICR 2019 language on sequencing.

Include the exact quote: "The ASH 2019 guideline panel suggests either TPO-RAs or rituximab as second-line therapy for adults with ITP of ≥3 months' duration; splenectomy may be deferred." Attach the guideline summary or title page.

4. Highlight bleeding risk (ITP) or transfusion burden (AIHA).

"Patient has WHO grade 2 bleeding: gum bleeding, epistaxis twice weekly, and menorrhagia requiring emergency-room visit Feb 2026 for epistaxis (no transfusion required but hemoglobin dropped to 10.1 g/dL). Delay of effective therapy risks progression to grade 3–4 bleeding including intracranial hemorrhage."

Denial: "Rituximab is off-label and experimental for ITP/AIHA"

Concrete steps:

1. Invoke ASH 2019 and Hill BJH 2024 by name.

"Rituximab 375 mg/m² weekly × 4 is recommended as second-line therapy for ITP in the ASH 2019 evidence-based guideline and for warm/cold AIHA in the Hill et al. British Journal of Haematology 2024 consensus review. Both are peer-reviewed, society-endorsed standards."

2. Cite the International Consensus Report (ICR) 2019.

"The ICR 2019 (Provan et al., Blood) lists rituximab as a standard second-line option for chronic ITP."

3. Reference your state's off-label coverage statute or the plan's own formulary language.

Many states and Medicare Advantage plans cover off-label uses if supported by recognized compendia (e.g., NCCN Drugs & Biologics Compendium, Clinical Pharmacology) or peer-reviewed literature. Check your Evidence of Coverage (EOC) document for "off-label drug" provisions and quote them.

4. Attach the ASH or Hill abstract/summary.

Medical directors are more likely to reverse denials when you provide the actual reference, not just a citation.

Denial: "Platelet count 35,000 is above our threshold of <30,000"

Concrete steps:

1. Provide bleeding documentation, not just CBC numbers.

"Patient platelet count 35,000 (April 10, 2026), but experiences daily wet purpura, gum bleeding while brushing teeth, and prolonged menses (7 days, heavy flow, hemoglobin dropped from 13.2 to 10.1 g/dL). WHO bleeding grade 2."

2. Document anticoagulant or antiplatelet need.

"Patient requires apixaban 5 mg BID for atrial fibrillation (CHA₂DS₂-VASc 4, prior TIA 2024); anticoagulation cannot be safely interrupted. Platelet count of 35,000 on anticoagulation poses unacceptable bleeding risk per treating hematologist."

3. Cite guidelines that use clinical context, not arbitrary thresholds.

ASH 2019 defines ITP treatment goals as "platelets sufficient to prevent clinically significant bleeding" and notes that the threshold varies by patient (e.g., need for anticoagulation, planned surgery, occupation). Quote this language.

4. Request peer-to-peer review.

Many plans allow your hematologist to speak directly with the insurer's medical director. Your hematologist can explain why a platelet count of 35,000 is inadequate in this patient's context. Request this in your appeal letter: "We request a peer-to-peer discussion between Dr. [Name], the treating hematologist, and the plan's medical director within 72 hours."

Denial: "Combination therapy (TPO-RA + Tavalisse or Wayrilz) not proven"

Concrete steps:

1. Explain distinct mechanisms.

"Promacta (TPO-RA) stimulates platelet production via the thrombopoietin receptor. Tavalisse (fostamatinib, SYK inhibitor) reduces platelet destruction by inhibiting Fcγ receptor signaling in splenic macrophages. These are complementary, not duplicate, mechanisms. ICR 2019 acknowledges combination therapy in refractory ITP."

2. Document refractory disease despite monotherapy.

"Patient on Promacta 75 mg daily × 6 months with partial response (platelets rose to 42,000 but remain <50,000 despite maximal dose). Bleeding symptoms persist (WHO grade 2). Addition of Tavalisse is appropriate per ICR 2019 definition of refractory ITP."

3. Cite published case series or trial sub-analyses.

While large RCTs of combination therapy are sparse, mention that the FDA label for Tavalisse and Wayrilz does not prohibit concurrent TPO-RA use, and ASH/ICR guidelines recognize multi-drug regimens in refractory cases.

4. Highlight failure of sequential monotherapy.

"Patient has failed corticosteroids, IVIG, rituximab, and achieved only partial response to Promacta monotherapy. ASH 2019 states that for patients with refractory ITP, no single best option exists; individualized multi-drug strategies are appropriate."

Denial: "Enjaymo (sutimlimab) for cold-agglutinin disease is not medically necessary"

Concrete steps:

1. Confirm the diagnosis meets FDA label criteria.

- DAT C3-positive (not just IgG).

- Cold-agglutinin titer ≥64 (some insurers use ≥128; cite your lab report).

- Recent transfusion history or symptomatic anemia despite steroids/rituximab.

2. Document transfusion frequency and symptomatic burden.

"Patient received 4 units pRBC over last 3 months (Jan, Feb, March, April 2026). Hemoglobin 7.8 g/dL pre-transfusion (April 12, 2026), with NYHA class II dyspnea and Karnofsky performance score 70. Acrocyanosis on cold exposure. One TIA episode Sept 2025 attributed to cold-agglutinin disease hyperviscosity."

3. Cite CARDINAL and CADENZA trials by name.

"Sutimlimab (Enjaymo) demonstrated statistically significant reduction in transfusion need and improvement in hemoglobin in the CARDINAL and CADENZA phase 3 trials, leading to FDA approval February 2022 for cold-agglutinin disease."

4. Show failure or contraindication to rituximab.

"Patient received rituximab 375 mg/m² × 4 (Dec 2025) with partial response (hemoglobin 9.6 g/dL, persistent hemolysis LDH 410). Re-treatment rituximab is of uncertain benefit per Hill BJH 2024; sutimlimab targets a distinct pathway (C1s inhibition)."

Denial: "Patient should try splenectomy before TPO-RA or other agents"

Concrete steps:

1. Cite ASH 2019 explicit language.

"ASH 2019 guideline states: 'We suggest either TPO-RA therapy or rituximab rather than splenectomy as second-line treatment' (conditional recommendation). Splenectomy is not a prerequisite."

2. Document surgical risk or patient refusal after informed consent.

- Age >65, cardiopulmonary comorbidity (COPD, heart failure), anticoagulation need.

- "Patient counseled on splenectomy risks (lifelong infection risk, need for vaccinations, surgical complications) and declines. ASH 2019 supports medical alternatives."

3. If splenectomy already performed, note outcome.

"Patient underwent laparoscopic splenectomy March 2024 with initial platelet rise to 180,000, then relapsed to 15,000 by December 2025. Post-splenectomy relapse is well-documented (30–40% by 5 years per ICR 2019); further medical therapy is appropriate."

What We Do

We help patients and families fight autoimmune cytopenia treatment denials by translating complex hematology into the language and evidence insurers respect. We draft appeal letters citing ASH 2019, ICR 2019, Hill BJH 2024, and the relevant FDA approvals (Tavalisse 2018, Wayrilz 2025, Enjaymo 2022, TPO-RAs 2008–2019); gather and organize your CBC trends, bleeding scores, transfusion logs, and prior-therapy documentation; prepare your hematologist for peer-to-peer review; and escalate to external review or state regulators when internal appeals fail. Our goal is a fast reversal so you can start the therapy your doctor ordered without dangerous delay.

Sources

1. American Society of Hematology. 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.

2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. (ICR 2019)

3. Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol. 2024;204(3):735–758.

4. US Food and Drug Administration. Promacta (eltrombopag) approval letter, August 2008; Nplate (romiplostim) approval letter, August 2008; Doptelet (avatrombopag) approval letter, November 2019; Tavalisse (fostamatinib) approval letter, April 2018; Wayrilz (rilzabrutinib) approval letter, August 29, 2025; Enjaymo (sutimlimab) approval letter, February 2022. Accessible at www.accessdata.fda.gov/scripts/cder/daf/.

5. Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021;384(14):1323–1334. (CARDINAL trial)

6. Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease / cold agglutinin syndrome. Blood. 2021;138(Supplement 1):2392. (Emerging BTK inhibitor data; rilzabrutinib LUNA-3 trial presented ASH 2024, published summary pending.)

7. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–2171.

8. Your state insurance department and Centers for Medicare & Medicaid Services (CMS) coverage determination search (for Medicare Advantage plans): www.cms.gov/medicare-coverage-database.

---

Disclaimer: This guide is educational and does not constitute legal or medical advice. Always work with your treating hematologist and consider consulting a patient advocate or attorney experienced in insurance appeals for your specific case.